Health Care · Pharmaceutical Preparations

FULC Fulcrum Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 168058183 filings
Russell 2000

FULC at a glance

Fulcrum Therapeutics, Inc. (FULC, SEC CIK 1680581) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as July 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$1.18.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Fulcrum Therapeutics, Inc. (FULC) shares worth $111.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by TANG KEVIN on July 17, 2026 of 50,945 shares at $3.52 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$111.2M · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Smaller reporting company status: Item 1A risk-factor disclosure omitted under Rule 12b-2
  • No newly added, updated, regulatory, operational, competitive, market, or financial risks disclosed this quarter

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales
  • Net loss $10.9M vs $19.6M YoY, operating expenses $13.9M vs $21.9M
  • Pociredir R&D expenses $1.9M vs $5.4M YoY, the largest program expense
  • Cash, equivalents and securities $306.5M at September 30, 2026
  • Operating cash used $48.2M vs $43.3M YoY, merger expected Q4 2026 with $275M dividend and $7.0M asset sale

AI summary of the FULC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 8.01: Other Events

  • Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash
  • Closing depends on the proposed Fulcrum-Slate merger, or necessary approvals if the merger terminates
Filed Aug 17, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • All-stock merger shifts Fulcrum into Slate Medicines, focusing the public company on migraine therapeutics
  • Fulcrum holders expected to own 5.0%; Slate holders 95.0%, subject to adjustment based on Fulcrum net cash

Item 5.01: Changes in Control of Registrant

  • Item 5.01 cross-references Item 1.01 for any control-change information
  • Investor impact depends on the transaction details disclosed under Item 1.01

Item EX-99.2: Item EX-99.2

  • Proposed stock-for-stock merger creates Slate Medicines, with Fulcrum holders receiving an estimated 5.0% of the combined company
  • $245 million private placement led by Frazier Life Sciences, funding Slate’s migraine pipeline and materially reshaping Fulcrum’s capital structure

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Item 5.02 contains no standalone officer or director change details
  • Investor-relevant information is incorporated from Item 1.01, requiring review of the material agreement terms

Item 7.01: Regulation FD Disclosure

  • Fulcrum and Slate announced execution of a merger agreement and purchase agreement on August 17, 2026
  • Transaction terms include exchange-ratio adjustments tied to Fulcrum’s closing net cash, affecting ownership and potential cash distributions

Item 1.01: Entry into a Material Definitive Agreement

  • Merger transforms Fulcrum into Slate Medicines, with Slate holders owning 55.9% and existing Fulcrum holders only 5.0% fully diluted
  • $245.0M concurrent investment provides planned capitalization, with investors receiving 39.1% of the combined company

Item 3.02: Unregistered Sales of Equity Securities

  • Slate shares issued in Concurrent Investment through private placements, exempt from SEC registration under Section 4(a)(2) and/or Regulation D
  • Unregistered issuance limits immediate public offering requirements but may create future dilution for existing Fulcrum shareholders
Filed Aug 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Principal accounting officer Greg Tourangeau departing Fulcrum on August 7, 2026
  • CFO Alan Musso appointed principal accounting officer effective August 7, 2026

AI summaries of FULC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for FULC

Don't miss the next FULC filing

  • Alerts as it files. A push when FULC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut FULC, by share count.
  • Ask anything. An AI agent that reads every FULC filing and answers with sources.

FULC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
TANG KEVINBuyJul 17, 2026$3.52
TANG KEVINBuyJul 16, 2026$3.56
TANG KEVINBuyJul 15, 2026$3.56
TANG KEVINBuyJul 14, 2026$3.56
TANG KEVINBuyJul 14, 2026$3.58
TANG KEVINBuyJul 13, 2026$3.54
Ezekowitz AlanSellJun 26, 2026$3.65
Lehrer-Graiwer JoshuaAApr 23, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.8M$80.0M$0
Operating Income-$110.7M-$21.9M-$84.8M
Net Income-$97.3M-$9.7M-$74.9M
Op. Margin-3945.2%-27.4%-
Net Margin-3470.1%-12.2%-
Balance Sheet
Total Assets-$260.7M$366.3M
Equity-$243.0M$349.0M
ROE--4.0%-21.5%
Per Share
EPS$-1.59$-0.16$-1.18
Cash Flow
Operating CF--$2.2M-$60.1M
CapEx-$278K$314K

Source: XBRL data in Fulcrum Therapeutics, Inc. (FULC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate FULC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
FULC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$111.2M
Q2 202624$108.2M
Q1 202626$132.3M
Q4 202524$175.7M
Q3 202524$128.8M
Q2 202526$101.2M
Q1 202524$27.1M
Q4 202418$39.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

FULC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KAug 17, 2026Analysis-
SC 13GAug 14, 2026-
8-KAug 10, 2026Analysis-
SC 13GAug 3, 2026-
10-QJul 30, 2026Analysis
4Jul 20, 2026--
SC 13GJul 17, 2026-
4Jul 15, 2026--
4Jun 30, 2026--
SC 13GJun 25, 2026-
SC 13GJun 25, 2026-
8-KJun 25, 2026Analysis-
8-KJun 11, 2026Analysis-
SC 13GJun 10, 2026-
8-KJun 4, 2026Analysis
8-KJun 1, 2026Analysis
4May 1, 2026--
8-KApr 27, 2026Analysis-
10-QApr 27, 2026Analysis
8-KFeb 24, 2026Analysis-
10-KFeb 24, 2026-
4Feb 4, 2026-
4Feb 4, 2026-

Related Health Care companies

All Health Care →

FULC SEC filings: frequently asked questions

Which institutions hold FULC stock?

As of September 30, 2026, the largest Fulcrum Therapeutics, Inc. (FULC) holders among the 13F filers tracked by SignalX were BlackRock ($43.0 million), D.E. Shaw & Co ($13.7 million), Vanguard Capital Management LLC ($10.6 million), Two Sigma Investments ($9.6 million), Renaissance Technologies LLC ($8.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was FULC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Fulcrum Therapeutics, Inc. (FULC) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $74.9 million. Diluted EPS was -$1.18. The figures come from the XBRL data in the 10-K.

What did FULC report in its latest 8-K?

Fulcrum Therapeutics, Inc. (FULC) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). Fulcrum agreed to sell early-stage HbF assets for approximately $7.0 million in cash.

What are the latest FULC SEC filings?

Fulcrum Therapeutics, Inc. (FULC) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on July 20, 2026.

What is FULC's SEC CIK number?

Fulcrum Therapeutics, Inc. (FULC)'s SEC Central Index Key (CIK) is 1680581. EDGAR lists every FULC filing under that number.

Ask anything about FULC

The research agent reads FULC's filings, financials, insider trades and 13F holders, then answers with sources.